FDX1 and neoplasm: We found that genetic mutation and deletion in FDX1 might decrease the level of MHC class I (MHC_I) so that it fails to efficiently bind peptides to MHC molecules and presents the endogenous antigen to CD8+ T cells, causing cytotoxic T lymphocytes to fail to recognize and kill tumor cells.